Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Inclusion Criteria:

• Written informed consent should be signed before implementing any trial-relatedprocedures
• Male or female, 18 years old ≤ age ≤ 75 years old
• Histopathologically or cytologically diagnosed as locally advanced intrahepaticcholangiocarcinoma
• No previous systemic treatment, More than 6 months after the end of postoperativeadjuvant therapy was allowed
• Expected survival time > 3 months
• At least ≥ 1 measurable lesions per RECIST 1.1
• ECOG PS scores 0-2
• Sufficient organ and bone marrow function
• Urine or serum pregnancy test is negative

Exclusion Criteria:

• Suffered from other malignant tumors in the past 5 years (except Radical basal cellcarcinoma of the skin squamous carcinoma of the skin and/or radical resected carcinomain situ)
• Ampullary tumor
• Received treatment from other clinical trials within 4 weeks before the first dose
• Received any anti-PD-1 antibody, anti-PD-L1/L2 antibody, anti-CTLA4 antibody, or otherimmunotherapy
• Suffered from severe cardiovascular disease within 12 months before enrollment, suchas symptomatic coronary heart disease, congestive heart failure ≥ Grade II,uncontrolled arrhythmia, and myocardial infarction
• Uncontrollable pleural effusion, pericardial effusion or ascites
• Use steroids or other systemic immunosuppressive therapies 4 weeks before enrollment
• Allergic reactions to the drugs used in this study
• HIV antibody positive, active hepatitis B or C (HBV, HCV)
• Known history of allogeneic organ transplantation and allogeneic hematopoietic stemcell transplantation
• other conditions that the investigator deems inappropriate for enrollment.